Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AstraZeneca PLC - American Depositary Shares (NQ:AZN)

69.73 +0.10 (+0.14%)
Streaming Delayed Price Updated: 9:52 AM EDT, Jul 8, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AstraZeneca PLC - American Depositary Shares

< Previous 1 2
...
15 16 17 18 19 20 21 22 23
...
67 68 Next >
What's Going On With Silence Therapeutics Stock Today?
Silence Therapeutics reports narrower Q4 loss, data from zerlasiran study, and strengthened cash position. In March 2024, Mallinckrodt notified Silence that they will not pursue further development of... 
Via Benzinga
AstraZeneca announces initiation of THARROS – a Phase III clinical trial investigating the potential of BREZTRI to improve cardiopulmonary outcomes in people with COPD
From AstraZeneca
Via Business Wire
Top Wall Street Analysts Flag US Market Concentration Anxiety, Advise Investors To Adopt 'Barbell Approach'
Goldman Sachs urges investors to diversify geographically due to high concentration in US tech stocks, with Japan, healthcare, and European GRANOLAS highlighted as promising markets. 
Via Benzinga
Pharma Stock Roundup: Novo Nordisk's New Obesity Pill Data, Roche, AstraZeneca's Pipeline Updates
This week, data from Novo Nordisk’s early-stage study on a new weight loss pill called amycretin showed that it could be more effective than Wegovy. Meanwhile, the FDA approved Johnson & Johnson's lung... 
Via Talk Markets
Check Out What Whales Are Doing With AZN
Via Benzinga
Medicare's Ambitious Drug Price Negotiation Plan: President Joe Biden Calls To Expand Targeted Medicines To 50 Annually by 2029
Explore President Biden's plan to expand Medicare drug negotiations, targeting at least 50 drugs annually. Uncover the impact on pharmaceutical profits and the broader health-care policy proposals,... 
Via Benzinga
Biden's State Of The Union: Grading His Results On Abortion Access, Drug Prices And Opium Epidemic
As President Biden prepares for his State of the Union address, he will address issues such as Bidenomics, healthcare, and the US's role in the world. 
Via Benzinga
Week In Review: Mabwell Sells Ex-China Rights To Rare Disease Therapy In $412 Million Deal
Mabwell, a Shanghai-San Diego biotech, sold ex-China rights for 9MW3011 to Disc Medicine of Watertown, MA in a deal worth up to $412 million. Meanwhile, AstraZeneca has returned most of the global... 
Via Talk Markets
Got $200? 2 Dividend Stocks to Buy and Hold Forever
Trust these two real estate stocks to be attractively priced and proven performers. 
Via The Motley Fool
2 Stocks That Could Turn $1,000 Into $2,500 in 5 Years
It will take a lot, but this goal isn't out of reach for these stocks. 
Via The Motley Fool
11 'Granolas' Stocks Outperform Magnificent 7 With Lower Volatility, Higher Yields
A group of stocks, which Goldman Sachs dubbed the "Granolas," accounted for 50% of gains of the Stoxx Europe 600 Index for the past year. 
Via Benzinga
3 Inflation-Resilient Stocks to Weather the Economic Turbulence
These are the undervalued inflation-resilient stocks to buy as they represent companies that have strong fundamentals. 
Via InvestorPlace
EXCLUSIVE: Vivani Medical Says Weight Loss/Diabetes Implant At Par With Novo Nordisk's Famed Injectable Wegovy/Ozempic, Animal Studies Shows
Vivani Medical unveils preclinical data on NPM-115, a twice-yearly exenatide subdermal implant for weight loss. Achieving a 20% reduction in high-fat diet-induced obese mice, comparable to Novo... 
Via Benzinga
Eli Lilly, Novo Nordisk's Strategies Against New Weight-Loss Drug Competitors
Zealand Pharma's drug showed positive results in 83% of patients in Phase 2 trials for MASH, heating up the race for new obesity drugs and pushing the company's shares 30% higher. 
Via Benzinga
MANDARA Phase III data published in New England Journal of Medicine show remission is an achievable goal in eosinophilic granulomatosis with polyangiitis (EGPA) with FASENRA
From AstraZeneca
Via Business Wire
Move Over Magnificent 7, Say Hello to the GRANOLAS
Dive into the compelling world of GRANOLAS stocks: Europe's elite players shaping the future of pharmaceuticals, tech, and consumer goods. 
Via InvestorPlace
Why AstraZeneca Stock Is Trading Higher Tuesday
FDA greenlights AstraZeneca's Tagrisso combo for advanced EGFRm NSCLC. FLAURA2 Phase 3 trial results reveal a 38% reduction in progression risk with Tagrisso plus chemo, outperforming monotherapy.... 
Via Benzinga
Datopotamab deruxtecan Biologics License Application accepted in the US for patients with previously treated advanced nonsquamous non-small cell lung cancer
From AstraZeneca
Via Business Wire
TAGRISSO® (osimertinib) demonstrated overwhelming efficacy benefit for patients with unresectable, Stage III EGFR-mutated lung cancer in LAURA Phase III trial
From AstraZeneca
Via Business Wire
Cruising For A Bruising
We’re currently living in the soft landing, and it is pleasant indeed. But inflation numbers at the start of the year have put us on notice. Like the Magnificent Seven, hopes of a sustained soft... 
Via Talk Markets
Topics Economy
Week In Review: LianBio To Close Operations; Will Pay $528 Million To Shareholders
LianBio, a Princeton-Shanghai biotech, has decided to call it quits. LianBio plans to stop all of its operations by the end of 2024, and it will distribute a $4.80 dividend/share ($528 million) to its... 
Via Talk Markets
TAGRISSO® (osimertinib) with the addition of chemotherapy approved in the US for patients with EGFR-mutated advanced lung cancer
From AstraZeneca
Via Business Wire
7 Contrarian Biotech Stocks to Consider Amid Sector Weakness
Although the healthcare innovation space has struggled recently, these contrarian biotech stocks now offer compelling discounts. 
Via InvestorPlace
7 Must-Buy Pharma Stocks Amid the Weight Loss Drug Revolution
Obesity drug sales boomed in 2023 and will continue in 2024. That could make these weight loss stocks even more attractive. 
Via InvestorPlace
Kerrisdale Capital Slams Altimmune (ALT) Stock in New Short Report
Kerrisdale Capital has released a short report, making clear why it is betting against ALT stock. Here's why Altimmune is likely in trouble. 
Via InvestorPlace
Move Aside, Eli Lilly and Novo Nordisk. Wall Street Thinks This Stock Will Be a Bigger Winner Over the Next 12 Months.
There's more for investors to get excited about in the biopharma world than just weight-loss drugs. 
Via The Motley Fool
This Analyst Slightly Lowers AstraZeneca Forecast Amid Earnings Concerns, Although Still Bullish on Future Growth Potential
AstraZeneca reported Q4 2023 sales of $12.02B, up 7%, below consensus. Excluding COVID-19 drugs, revenue increased by 16%. Core EPS was $1.45, missing consensus. BMO Capital maintains Outperform... 
Via Benzinga
AstraZeneca Leads The FTSE Lower On Barclay’s Downgrade
The pharmaceutical sector saw a decline of 1.6%, with AstraZeneca dropping 2.4% after Barclays lowered its price target for the stock. 
Via Talk Markets
From Slack To Surveillance: Here's How Companies Monitor Your Communications With AI
In a move reminiscent of George Orwell's surveillance dystopia, companies are now deploying artificial intelligence (AI) to monitor communications on platforms like Slack and Microsoft Teams. 
Via Benzinga
Topics Artificial Intelligence
Got $5,000? These 3 Stocks Are Near Their 52-Week Lows and Are Underrated Buys
These stocks all trade at less than 17 times their future expected earnings. 
Via The Motley Fool
< Previous 1 2
...
15 16 17 18 19 20 21 22 23
...
67 68 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.